A medication treating joints may also be quietly protecting hearts
For decades, methotrexate has stood as a frontline defense against the joint destruction of rheumatoid arthritis. Now, a study from Flinders University suggests the drug carries a quieter gift: a meaningful reduction in blood pressure that may shield the heart from attack and stroke. In a population already burdened by elevated cardiovascular risk, the discovery that a familiar medicine works on two fronts at once invites a deeper reckoning with how well we truly understand the tools we have long relied upon.
- Rheumatoid arthritis patients face a double jeopardy — the same chronic inflammation that erodes their joints also quietly damages their cardiovascular system.
- A six-month trial of 62 newly diagnosed patients revealed methotrexate lowered systolic blood pressure by 7.4 mmHg more than sulfasalazine — a gap cardiologists consider clinically significant.
- Most unsettling to existing assumptions: the blood pressure benefit appeared whether or not patients' arthritis actually improved, suggesting the drug is acting on the heart through an entirely separate biological pathway.
- Genetic analysis of trial participants identified variants that predicted who would respond most strongly, opening a door toward precision prescribing based on individual cardiovascular profiles.
- Researchers caution the mechanism is not yet fully mapped, and larger studies are needed — but the implication is already reshaping how a decades-old drug is understood.
Methotrexate has treated rheumatoid arthritis for generations, its value measured almost entirely in joint relief. A new study from Flinders University and Southern Adelaide Local Health Network is now asking whether that accounting has always been incomplete.
Tracking 62 newly diagnosed arthritis patients over six months, researchers split participants between methotrexate and sulfasalazine, measuring blood pressure, joint inflammation, and arterial stiffness at regular intervals. The result was striking: methotrexate reduced systolic blood pressure by an average of 7.4 mmHg compared to sulfasalazine — a difference cardiologists regard as clinically meaningful, one capable of reducing the likelihood of serious cardiac events.
What deepened the finding was its independence from arthritis outcomes. The blood pressure benefit appeared regardless of whether a patient's joint symptoms improved, pointing to a separate mechanism — perhaps systemic inflammation reduction or a fundamental improvement in blood vessel function — that operates in parallel with the drug's better-known effects. Professor Arduino Mangoni, who led the research, sees in this a new understanding of what methotrexate actually does inside the body.
The team also found that genetic variation among patients predicted the strength of the blood pressure response, raising the prospect of genetic screening to identify who stands to gain the most cardiovascular protection from the drug. For a population already at elevated heart risk simply by virtue of their diagnosis, that possibility carries real weight.
Dr. Sara Tommasi, the study's coordinator, is careful to note that the mechanism remains incompletely understood and that further research is needed. Still, the broader implication is difficult to set aside: millions of people taking methotrexate for their joints may already be receiving a form of cardiac protection they never knew to expect.
Methotrexate has been treating rheumatoid arthritis for decades. Now researchers have discovered it does something else entirely: it lowers blood pressure in ways that could meaningfully reduce the risk of heart attack and stroke.
The finding comes from a six-month study led by Flinders University and Southern Adelaide Local Health Network researchers who tracked 62 newly diagnosed arthritis patients. Half received methotrexate, the other half sulfasalazine, a different arthritis medication. The team measured blood pressure, joint inflammation, and arterial stiffness at the start, then again at one month and six months. What they found was striking: methotrexate reduced systolic blood pressure—the force blood exerts against artery walls when the heart beats—by an average of 7.4 millimeters of mercury compared to sulfasalazine. That may sound modest, but cardiologists consider even small drops in blood pressure clinically significant. A reduction of that magnitude can meaningfully lower the odds of serious cardiac events.
Rheumatoid arthritis affects roughly one in every hundred people. It's an autoimmune disease that triggers inflammation and pain in the joints' connective tissue. For those living with it, the condition itself carries cardiovascular risk—the chronic inflammation that damages joints also damages the heart. Methotrexate has long been the first-line treatment, but its mechanism was thought to work solely through anti-inflammatory action on the joints themselves.
What makes this study unusual is what didn't happen. The blood pressure benefit appeared independent of how much patients' arthritis improved. Some people's joint symptoms got better, others' didn't—but the blood pressure drop occurred regardless. This suggests methotrexate is protecting the heart through a separate pathway, possibly by calming systemic inflammation or by improving how blood vessels function at a fundamental level. Professor Arduino Mangoni, who led the research, notes that this opens a new understanding of what the drug actually does in the body.
The researchers went further. They examined genetic variation among the patients and found that certain gene variants predicted who would experience the strongest blood pressure response to methotrexate. This matters because it points toward a future where doctors could use genetic testing to identify which arthritis patients would gain the most heart-protective benefit from the drug—a form of precision medicine that could reshape how the medication is prescribed and monitored.
Dr. Sara Tommasi, the study coordinator, emphasizes that while the findings are promising, the mechanism remains incompletely understood. More research will be needed to confirm the results and to map exactly how methotrexate achieves this blood pressure effect. But the implications are already clear: a medication that millions of people take for joint disease may also be quietly protecting their hearts. For patients with rheumatoid arthritis—a group already at elevated cardiovascular risk—that secondary benefit could prove as important as the primary one.
Citas Notables
Even a small drop in blood pressure can lower the risk of serious heart problems like heart attacks and strokes— Professor Arduino Mangoni, Flinders University
This well-known arthritis drug could also play a role in protecting heart health, especially in people at higher risk due to inflammation— Dr. Sara Tommasi, study coordinator
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that the blood pressure drop happened independent of arthritis improvement?
Because it tells us methotrexate isn't just working through one pathway. If the heart benefit only appeared when joints got better, we'd assume it was all about reducing inflammation in the joints. But it happened anyway, which means the drug is doing something systemic—something that protects the cardiovascular system directly.
Seven point four millimeters of mercury sounds small. Why is that considered meaningful?
In blood pressure terms, small is actually powerful. The difference between a population that drops 7.4 mmHg and one that doesn't is measurable in heart attacks and strokes prevented. It's not a cure, but it's the kind of shift that shows up in mortality data.
The genetic angle—what does that actually mean for a patient?
Right now, it means nothing yet. But eventually it could mean a blood test before starting methotrexate that tells you whether you're likely to get this heart benefit. Some people might get it, others might not, based on their genes. That's the promise of personalized medicine.
Does this change how doctors should prescribe methotrexate today?
Not immediately. The study is one piece of evidence. But it does give rheumatoid arthritis patients another reason to take the drug as prescribed—they're not just treating their joints, they're potentially protecting their hearts too.
What's the next question researchers need to answer?
How does it actually work? Is it reducing inflammation throughout the body? Improving endothelial function? Making blood vessels more elastic? Until we know the mechanism, we can't predict who benefits most or whether we could enhance the effect.